SIC 2834 – Pharmaceutical Preparations
| Valuation | |
|---|---|
| Market Cap ($M) | 1,440.11 |
| Enterprise Value ($M) | 1,080.71 |
| Book Value ($M) | 352.02 |
| Book Value / Share | 2.24 |
| Price / Book | 4.09 |
| NCAV ($M) | 334.66 |
| NCAV / Share | 2.13 |
| Price / NCAV | 4.30 |
| Profitability (mra) | |
|---|---|
| Return on Invested Capital (ROIC) | -0.41 |
| Return on Assets (ROA) | -1.07 |
| Return on Equity (ROE) | -22.20 |
| Liquidity (mrq) | |
|---|---|
| Quick Ratio | 12.94 |
| Current Ratio | 13.01 |
| Balance Sheet (mrq) ($M) | |
|---|---|
| Current Assets | 473.01 |
| Assets | 490.37 |
| Liabilities | 138.35 |
| Debt | n/a |
| Equity | n/a |
| Income Statement (mra) ($M) | |
|---|---|
| Revenue | 0.00 |
| Operating Income | 0.00 |
| Net Income | 0.00 |
| Earnings Per Share Basic And Diluted | n/a |
| Earnings Per Share Diluted | n/a |
| Earnings Per Share Basic | n/a |
| Cash Flow Statement (mra) ($M) | |
|---|---|
| Cash From Operations | 0.00 |
| Cash from Investing | 0.00 |
| Cash from Financing | 0.00 |
(click for more detail) |
|
| File Date | Form | Activist 13D/G Investors | Ownership (%) |
Change (%) |
|---|---|---|---|---|
| 13G | Avoro Capital Advisors LLC | 7.90 | ||
| 13G/A | Venrock Healthcare Capital Partners III, L.P. | 8.70 | 76.96 | |
| 13G/A | Vanguard Group Inc | 5.37 | 0.00 | |
| 13G/A | BlackRock, Inc. | 7.30 | 0.00 | |
| 13D/A | Summer Road Llc | 9.40 | 6.93 | |
| 13G/A | Opaleye Management Inc. | 5.51 | -0.08 | |
| 13G | Deep Track Capital, LP | 8.38 |
| Top 13F Investors | Shares (1000) |
Change (%) |
Value ($1000) |
Change (%) |
|---|---|---|---|---|
(click for more detail) |
||||
| Date | Insider Trades | Code | Shares | Value |
|---|---|---|---|---|
(click for more detail) |
||||
| File Date | Form | SEC Filings |
|---|---|---|
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q | ||
| UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-K | ||
(click for more detail) |
||
| Short Volume | |||
|---|---|---|---|
| Market Date | Short Volume | Total Volume | Short Volume Ratio |
| 297,500 | 1,202,165 | 24.75 | |
| 199,923 | 1,087,017 | 18.39 | |
| 376,123 | 1,259,174 | 29.87 | |
| 190,667 | 703,985 | 27.08 | |
(click for more detail) |
|||
| Similar Companies | |
|---|---|
| NRIX – Nurix Therapeutics, Inc. | NTLA – Intellia Therapeutics, Inc. |
| OCS – Oculis Holding AG | OMER – Omeros Corporation |
| PAHC – Phibro Animal Health Corporation |